kidney disease
NHS England approves delayed-release treatment for rare kidney disease
August 10, 2026NHS England, kidney disease, ultra-rare inherited disorder
NHS England has approved the routine commissioning of delayed-release mercaptamine bitartrate for eligible patients with nephropathic cystinosis, providing an additional …
Takeda presents positive results from trial of chronic kidney disease treatment
June 10, 2025Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease
Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …
NICE recommends treatment for chronic kidney disease, IgA nephropathy
May 23, 2025Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …
EU approval granted for rare kidney disease treatment
April 29, 2025Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology
The EU has granted marketing authorisation (MA) for Filspari – CSL Vifor and Travere Therapeutics’ therapy for primary IgA nephropathy …
Renalys Pharma closes ¥6bn series A financing for kidney disease treatments in Asia
July 17, 2024Business Services Financing, Nephrology, kidney disease, renalys Pharma
Renalys Pharma has announced that it has completed ¥6bn series A financing, which was led by Catalys Pacific and SR …
AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment
November 6, 2023Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria
AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …
Novartis acquires Chinook Therapeutics for $3.5bn
June 12, 2023Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …
AstraZeneca drug approved by FDA for kidney disease treatment
May 4, 2021Manufacturing and Production AstraZeneca, FDA, kidney disease, pharma, pharma news
AstraZeneca’s Farxiga drug has been approved for the treatment of chronic kidney disease (CKD) in the US by the FDA.
Evotec and Chinook to partner on new kidney disease treatments
March 1, 2021Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease
Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …
Akebia Therapeutics’ HIF-PH inhibitor passes efficacy goals in chronic kidney disease without dialysis, but falls short on safety
September 4, 2020Medical Communications, Research and Development Akebia Therapeutics, kidney disease, pharma, vadadustat
Akebia Therapeutics has pulled back the veil on data from the second of two Phase 3 clinical trials for its …
NICE does not recommend cancer drug combination to the NHS
February 13, 2020Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease
NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …
Top Ten most popular articles on Pharmafile.com this week!
April 18, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GSK, Genentech, Gilead, HIV, MS, Novartis, kidney disease, pharma
This week was a good one for clinical trials and a bad one for employees after both Gilead and GSK …
Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care
October 4, 2018Research and Development Mayo Clinic, baxter, kidney disease, pharma, renal
American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a bid to establish a “renal …
J&J stops Invokana trial early after success in kidney disease and type 2 diabetes
July 17, 2018Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes
Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …
SMC approves first ever treatment for genetic kidney disease
January 12, 2016Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan
The Scottish Medicines Consortium (SMC) has approved Otsuka’s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …
Latest content
Five Facts about cardiovascular disease
